Govcon Giants


Text 786-477-0477

AstraZeneca Awarded $60M Contract To Manufacture Antibody Products

 In Contract Awards

AstraZeneca, Gaithersburg, Maryland, was awarded a $60,000,000 firm-fixed-price contract to manufacture AZD7442, a combination antibody product intended to prevent or treat clinical effects of SARS-CoV-2, for a minimum of 100,000 treatment courses. Work will be performed in Gaithersburg, Maryland, with an estimated completion date of June 30, 2021. Fiscal 2020 Army general funds in the amount of $30,000,000 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity (W911QY-20-C-0119). (Awarded Sept. 30, 2020)

AstraZeneca Pharmaceuticals (AstraZeneca US), a subsidiary of UK-based global drugmaker AstraZeneca, is a significant player in the US pharmaceuticals market. The company’s sales represent about a third of its parent’s revenues. AstraZeneca US’ treatments focus on several therapeutic areas: cardiovascular, renal, metabolic, oncology, and respiratory disorders. Its best-known products include asthma medicine Symbicort; cancer drugs Tagrisso, Faslodex, and Imfinzi; and cardiovascular treatments Brilinta and Farxiga (cardiovascular). The company operates several R&D and manufacturing locations across the US.(


Recommended Posts

Leave a Comment